A Phase 3, Double-Blind, Placebo-controlled Study of Quizartinib Administered in Combination With Induction and Consolidation Chemotherapy, and Administered as Maintenance Therapy in Subjects 18 to 75 Years Old With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia

Trial Profile

A Phase 3, Double-Blind, Placebo-controlled Study of Quizartinib Administered in Combination With Induction and Consolidation Chemotherapy, and Administered as Maintenance Therapy in Subjects 18 to 75 Years Old With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia

Recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Oct 2017

At a glance

  • Drugs Quizartinib (Primary) ; Cytarabine; Daunorubicin; Idarubicin
  • Indications Acute myelomonocytic leukaemia; Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Acronyms QuANTUM-First study
  • Sponsors Daiichi Sankyo Inc
  • Most Recent Events

    • 12 Oct 2017 Trial design presented at the 42nd European Society for Medical Oncology Congress.
    • 31 Aug 2017 According to a Daiichi Sankyo media release, trial design will be presented at the European Society for Medical Oncology (ESMO) 2017 Congress.
    • 14 Aug 2017 Planned End Date changed from 1 Jan 2020 to 1 Nov 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top